GSK’s vaccines group — including R&D — faces heavy job cuts in latest restructuring
Emma WalmsleyGSK’s top executives stayed mum yesterday on the location and number of layoffs likely to occur as the pharma giant integrated their vaccine R&D ops with the pharma side of the business. But it’s clear now that the ax will fall hard on the European vaccine group, with 935 jobs on the chopping block in Belgium and many more rumored cuts under discussion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
